Sunshine finally: Ranbaxy gets FDA ok for Diovan generic
This article was originally published in Scrip
Finally, the sun seems to be shining on Ranbaxy. Ending prolonged speculation on the fate of its generic version of Novartis's blockbuster blood pressure treatment Diovan (valsartan) amid mounting pressure from competitors, Ranbaxy said it had received US FDA approval for the product on an "exclusive basis."
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.